08:10 AM EDT, 08/14/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Thursday it has priced an underwritten offering of about 21.3 million common shares at $4 apiece for expected gross proceeds of $85 million.

The company plans to use the net proceeds, along with its current cash and cash equivalents, to support the launch and marketing of Anaphylm Sublingual Film to treat allergic reactions, and for working capital, capital expenses and general corporate purposes, it added.

Aquestive Therapeutics ( AQST ) also said it anticipates the offering to close around Friday.